BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roslind A, Johansen JS. YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation. Methods Mol Biol 2009;511:159-84. [PMID: 19347297 DOI: 10.1007/978-1-59745-447-6_7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro Oncol 2012;14:1215-26. [PMID: 22962413 DOI: 10.1093/neuonc/nos157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
2 Roca-Rivada A, Bravo SB, Pérez-Sotelo D, Alonso J, Castro AI, Baamonde I, Baltar J, Casanueva FF, Pardo M. CILAIR-Based Secretome Analysis of Obese Visceral and Subcutaneous Adipose Tissues Reveals Distinctive ECM Remodeling and Inflammation Mediators. Sci Rep 2015;5:12214. [PMID: 26198096 DOI: 10.1038/srep12214] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
3 Rathcke CN, Vestergaard H. YKL-40--an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61. [PMID: 19930630 DOI: 10.1186/1475-2840-8-61] [Cited by in Crossref: 115] [Cited by in F6Publishing: 115] [Article Influence: 8.8] [Reference Citation Analysis]
4 Chavan V, Sabavath S, Babu CH, Boyapati L. Estimation of YKL-40 Acute-Phase Protein in Serum of Patients with Periodontal Disease and Healthy Individuals: A Clinical-Biochemical Study. Contemp Clin Dent 2019;10:249-55. [PMID: 32308286 DOI: 10.4103/ccd.ccd_471_18] [Reference Citation Analysis]
5 Tao H, Yang J, Shi K, Huang C, Zhang L, Lv X, Li J. The significance of YKL-40 protein in liver fibrosis. Inflamm Res 2014;63:249-54. [DOI: 10.1007/s00011-013-0698-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
6 Muszyński P, Groblewska M, Kulczyńska-Przybik A, Kułakowska A, Mroczko B. YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease. Curr Neuropharmacol 2017;15:906-17. [PMID: 28183245 DOI: 10.2174/1570159X15666170208124324] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
7 Keles ZP, Keles GC, Avci B, Cetinkaya BO, Emingil G. Analysis of YKL-40 Acute-Phase Protein and Interleukin-6 Levels in Periodontal Disease. Journal of Periodontology 2014;85:1240-6. [DOI: 10.1902/jop.2014.130631] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
8 Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, Gøtze JP, Johansen JS, Kastrup J; The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflamm Res 2011;60:281-7. [DOI: 10.1007/s00011-010-0266-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
9 Morera E, Steinhäuser SS, Budkova Z, Ingthorsson S, Kricker J, Krueger A, Traustadottir GA, Gudjonsson T. YKL-40/CHI3L1 facilitates migration and invasion in HER2 overexpressing breast epithelial progenitor cells and generates a niche for capillary-like network formation. In Vitro Cell Dev Biol Anim 2019;55:838-53. [PMID: 31482369 DOI: 10.1007/s11626-019-00403-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Kurt A, Kılıç R, Tad M, Polat OA. YKL-40 expression in pterygium: a potential role in the pathogenesis. Int Ophthalmol 2019;39:1445-50. [PMID: 29922975 DOI: 10.1007/s10792-018-0957-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Dönder A, Özdemir HH. Serum YKL-40 levels in patients with multiple sclerosis. Arq Neuropsiquiatr 2021;79:795-8. [PMID: 34669813 DOI: 10.1590/0004-282X-ANP-2020-0326] [Reference Citation Analysis]
12 Yan L, Deng Y, Zhou J, Zhao H, Wang G; China HepB-Related Fibrosis Assessment Research Group. Serum YKL-40 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT. Infection 2018;46:385-93. [PMID: 29600444 DOI: 10.1007/s15010-018-1136-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
13 Lee DH, Han JH, Lee YS, Jung YS, Roh YS, Yun JS, Han SB, Hong JT. Chitinase-3-like-1 deficiency attenuates ethanol-induced liver injury by inhibition of sterol regulatory element binding protein 1-dependent triglyceride synthesis. Metabolism 2019;95:46-56. [PMID: 30935969 DOI: 10.1016/j.metabol.2019.03.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Richter B, Roslind A, Hesse U, Nordling J, Johansen JS, Horn T, Hansen AB. YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology 2010;57:371-83. [PMID: 20840668 DOI: 10.1111/j.1365-2559.2010.03640.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
15 Xu X, Ma H, Xu J, Huang H, Wu X, Xiong Y, Zhan H, Huang F. Elevation in circulating YKL-40 concentration in patients with cerebrovascular disease. Bosn J Basic Med Sci 2014;14:120-4. [PMID: 25172968 DOI: 10.17305/bjbms.2014.3.42] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Jiang Z, Wang S, Jin J, Ying S, Chen Z, Zhu D, Xiao B, Hu Y, Qian Y, Cai T, Fu L. The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases. J Clin Lab Anal 2020;34:e23200. [PMID: 31916309 DOI: 10.1002/jcla.23200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
17 Jefri M, Huang YN, Huang WC, Tai CS, Chen WL. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer 2015;15:590. [PMID: 26275425 DOI: 10.1186/s12885-015-1592-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 5.1] [Reference Citation Analysis]
18 Hermansson L, Yilmaz A, Axelsson M, Blennow K, Fuchs D, Hagberg L, Lycke J, Zetterberg H, Gisslén M. Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. J Neuroinflammation 2019;16:16. [PMID: 30678707 DOI: 10.1186/s12974-019-1404-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
19 Greenwell-Wild T, Moutsopoulos NM, Gliozzi M, Kapsogeorgou E, Rangel Z, Munson PJ, Moutsopoulos HM, Wahl SM. Chitinases in the salivary glands and circulation of patients with Sjögren’s syndrome: macrophage harbingers of disease severity. Arthritis Rheum. 2011;63:3103-3115. [PMID: 21618203 DOI: 10.1002/art.30465] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.7] [Reference Citation Analysis]
20 Schultz NA, Johansen JS. YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers (Basel) 2010;2:1453-91. [PMID: 24281168 DOI: 10.3390/cancers2031453] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
21 Bhardwaj R, Yester JW, Singh SK, Biswas DD, Surace MJ, Waters MR, Hauser KF, Yao Z, Boyce BF, Kordula T. RelB/p50 complexes regulate cytokine-induced YKL-40 expression. J Immunol 2015;194:2862-70. [PMID: 25681350 DOI: 10.4049/jimmunol.1400874] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
22 Palermo AT, Palmer RE, So KS, Oba-Shinjo SM, Zhang M, Richards B, Madhiwalla ST, Finn PF, Hasegawa A, Ciociola KM, Pescatori M, McVie-Wylie AJ, Mattaliano RJ, Madden SL, Marie SK, Klinger KW, Pomponio RJ. Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients. Mol Genet Metab 2012;106:287-300. [PMID: 22658377 DOI: 10.1016/j.ymgme.2012.05.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
23 Li L, Fan J, Li D, Liu Y, Shrestha P, Zhong C, Xia X, Huang X. Influence of YKL-40 gene RNA interference on the biological behaviors of endometrial cancer HEC-1A cells. Oncol Lett 2018;16:1777-84. [PMID: 30008865 DOI: 10.3892/ol.2018.8814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Lee SH, Lin CY, Wang PH, Han CP, Yang SF, Chang JT, Lee MC, Lin LY, Lee MS. Significant association of elevated concentration of plasma YKL-40 with disease severity in patients with pelvic inflammatory disease. J Clin Lab Anal 2012;26:136-42. [PMID: 22628227 DOI: 10.1002/jcla.21500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
25 Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. Proc Am Thorac Soc 2012;9:74-9. [PMID: 22550249 DOI: 10.1513/pats.201107-039MS] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
26 Szymańska-Chabowska A, Juzwiszyn J, Jankowska-Polańska B, Tański W, Chabowski M. Chitinase 3-Like 1, Nestin, and Testin Proteins as Novel Biomarkers of Potential Clinical Use in Colorectal Cancer: A Review. Adv Exp Med Biol 2020;1279:1-8. [PMID: 32170669 DOI: 10.1007/5584_2020_506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Syed Ikmal SI, Zaman Huri H, Vethakkan SR, Wan Ahmad WA. Potential biomarkers of insulin resistance and atherosclerosis in type 2 diabetes mellitus patients with coronary artery disease.Int J Endocrinol. 2013;2013:698567. [PMID: 24282409 DOI: 10.1155/2013/698567] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
28 Vom Dorp F, Tschirdewahn S, Niedworok C, Reis H, Krause H, Kempkensteffen C, Busch J, Kramer G, Shariat SF, Nyirady P, Rübben H, Szarvas T. Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. J Urol 2016;195:1120-5. [PMID: 26454102 DOI: 10.1016/j.juro.2015.09.084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kyrgios I, Galli-Tsinopoulou A, Stylianou C, Papakonstantinou E, Arvanitidou M, Haidich AB. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Metabolism 2012;61:562-8. [PMID: 22036069 DOI: 10.1016/j.metabol.2011.09.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
30 Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol 2009;5:1065-82. [PMID: 19792974 DOI: 10.2217/fon.09.66] [Cited by in Crossref: 96] [Cited by in F6Publishing: 106] [Article Influence: 7.4] [Reference Citation Analysis]
31 Adrangi S, Faramarzi MA. From bacteria to human: a journey into the world of chitinases. Biotechnol Adv. 2013;31:1786-1795. [PMID: 24095741 DOI: 10.1016/j.biotechadv.2013.09.012] [Cited by in Crossref: 125] [Cited by in F6Publishing: 109] [Article Influence: 13.9] [Reference Citation Analysis]
32 Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JL, Chalermchai T, Krebs SJ, Robb ML, Hellmuth J, Gisslén M, Zetterberg H, Spudich S; RV254SEARCH 010, RV304SEARCH 013, and SEARCH 011 Study Teams. Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS 2017;31:247-52. [PMID: 27819802 DOI: 10.1097/QAD.0000000000001314] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
33 Bikker FJ, Nascimento GG, Nazmi K, Silbereisen A, Belibasakis GN, Kaman WE, Lopez R, Bostanci N. Salivary Total Protease Activity Based on a Broad-Spectrum Fluorescence Resonance Energy Transfer Approach to Monitor Induction and Resolution of Gingival Inflammation. Mol Diagn Ther 2019;23:667-76. [PMID: 31372941 DOI: 10.1007/s40291-019-00421-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Radchenko VV, Il'nitskaia EV, Tret'iakov VE, Serebriakova MV, Storozheva ZI, Shuvaeva TM, Lipkin VM. [Identification in the rat olfactory epithelium new subgroup YM-1 chitinase-like protein]. Bioorg Khim 2010;36:646-53. [PMID: 21063451 DOI: 10.1134/s1068162010050079] [Reference Citation Analysis]
35 Kazakova M, Batalov A, Deneva T, Mateva N, Kolarov Z, Sarafian V. Relationship between sonographic parameters and YKL-40 levels in rheumatoid arthritis. Rheumatol Int 2013;33:341-6. [PMID: 22451025 DOI: 10.1007/s00296-012-2387-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]